The CB2R Modulator with Concurrent Upregulation of ERα from Cimicifuga racemosa Suppresses Bone Resorption of Osteoclasts Through the Inhibition of Autophagy and Lysosome Functions
Pharmaceuticals · 18.11.2026 · 19 (11) · 1838
DOI: 10.3390/ph19111838 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 18.11.2026. Verfasst von Si-Jing Hu und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background/Objectives: Cimicifuga racemosa (CR), a botanical widely used for postmenopausal osteoporosis (PMOP), concurrently functionally engages cannabinoid receptor 2 (CB2R) and estrogen receptor α (ERα), but the downstream signaling pathways remain to be fully elucidated. This study aimed to identify CR-derived constituents with dual binding potential for CB2R and ERα and to elucidate their mechanism of action in osteoclastogenesis.
Methods
A structure-informed pipeline integrating machine learning classification, hierarchical molecular docking, and molecular dynamics simulations was established to screen for CB2R modulators. Candidate compounds were validated using relative luminescence assays, cyclic adenosine monophosphate measurements, ERα concentration assays, cellular thermal shift assays, and co-immunoprecipitation analyses. Transcriptomic profiling coupled with Gene Ontology slim enrichment was performed to delineate CB2R and ERα regulatory networks in osteoclasts (OCs). Anti-osteoclastogenic effects and downstream mechanisms were investigated in RAW264.7-derived OCs, with pharmacological inhibition of CB2R and ERα confirming target specificity.
Results
Among 431 compounds, cimigenol-3-one was identified as a CB2R agonist-like compound that increased ERα protein levels and required ERα for its anti-osteoclastogenic effects. It inhibited RANKL-induced osteoclastogenesis, disrupted F-actin rings, and downregulated key bone-resorptive genes. Mechanistically, it disrupted lysosomal function (reduced Lis1, Rab7, and Lamp2) and suppressed autophagic flux (inhibited Beclin-1 and ATGs). Genetic knockdown or pharmacological blockade of CB2R and ERα reversed these effects, confirming that coordinated receptor activation disrupts lysosomal homeostasis and autophagy.
Conclusions
Cimigenol-3-one, identified from CR via AI-assisted screening, acted as the CB2R modulator with concurrent upregulation of ERα to suppress osteoclast bone resorption by disrupting lysosomal function and autophagic flux.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Hu, S., Chen, G., Shan, M., Yan, Y., Song, Z., Cheng, G., Zhang, Q., Qin, L., & Han, T. (2026). The CB2R Modulator with Concurrent Upregulation of ERα from Cimicifuga racemosa Suppresses Bone Resorption of Osteoclasts Through the Inhibition of Autophagy and Lysosome Functions. Pharmaceuticals, 19(11), 1838. https://doi.org/10.3390/ph19111838
Vancouver
Hu S, Chen G, Shan M, Yan Y, Song Z, Cheng G, et al. The CB2R Modulator with Concurrent Upregulation of ERα from Cimicifuga racemosa Suppresses Bone Resorption of Osteoclasts Through the Inhibition of Autophagy and Lysosome Functions. Pharmaceuticals. 2026;19(11):1838. doi:10.3390/ph19111838
BibTeX
@article{Hu2026,
author = {Hu, Si-Jing and Chen, Gao-Ce and Shan, Meng-Yi and Yan, Yu-Yuan and Song, Zi-Le and Cheng, Gang and Zhang, Qiao-Yan and Qin, Lu-Ping and Han, Ting},
title = {The CB2R Modulator with Concurrent Upregulation of ERα from Cimicifuga racemosa Suppresses Bone Resorption of Osteoclasts Through the Inhibition of Autophagy and Lysosome Functions},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1838},
doi = {10.3390/ph19111838}
}
EUVIMED